Data compiled by Redley Lamar · ChainSifter Intelligence
1Suppliers
3Customers
3Debt Items
6Related Chains
Source-Backed Evidence Depth
Black Diamond Therapeutics, Inc. (BDTX) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
8Total relationships
1Distinct source URLs
5High confidence
0.810Average confidence
2026-09-13Latest database update
ChainSifter does not infer unreported suppliers, customers, ownership, acquisitions, debt exposure, revenue dependency, or future supply-chain events on this public page.
Reciprocal relationship from AVBP graph: Reciprocal relationship from BDTX graph: Reciprocal relationship from AVBP graph: therwise prefer to develop and market ourselves. We also face substantial co…
Black Diamond Therapeutics, Inc. Customers
Ticker
Name
Confidence
Evidence
SERVIER-PHARMACEUTICALS-LLC
SERVIER-PHARMACEUTICALS-LLC
92%
On March 18, 2025, the Company entered into a global licensing agreement (the Servier Agreement) with Servier Pharmaceuticals LLC (Servier) for BDTX-4933, a small molecule designed by the Company to …
BLACK-DIAMOND-THERAPEUTICS-SECURITY-CORPORATION
BLACK-DIAMOND-THERAPEUTICS-SECURITY-CORPORATION
62%
ed substantially all of its efforts to raising capital, obtaining financing and incurring research and development costs related to the development and advancement of its product candidates identifie…
REVELIO-THERAPEUTICS-INC
REVELIO-THERAPEUTICS-INC
62%
net consisted of the following: March 31, 2026 December 31, 2025 Leasehold improvements $ 1,593 $ 1,593 Property and equipment 1,593 1,593 Less: accumulated depreciation ( 1,255 ) ( 1,228 ) Total Pro…
Black Diamond Therapeutics, Inc. Debt Obligations
Instrument
Description
Confidence
Evidence
BDTX-DEBT
Debt stack $17.9M
90%
Market cache reports total debt of $17.9M.
BDTX-DEBT-8127
Warrants outstanding: 16000
90%
xbrl warrant detail from xbrl 2020-12-31.
BDTX-DEBT-8128
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2020-12-31.
Black Diamond Therapeutics, Inc. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Black Diamond Therapeutics, Inc..
Black Diamond Therapeutics, Inc. Ownership
Holder
Name
Confidence
Evidence
BDTX-OWNER-T-ROWE-PRICE-INVESTMENT-MANAGEME
T. Rowe Price Investment Management, Inc.
90%
13F overlay lists T. Rowe Price Investment Management, Inc. as top holder; 106 tracked holders.
Black Diamond Therapeutics, Inc. Extended Supply Chain Network
